DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
To assess the effect of AZD6738 and Durvalumab combination or AZD6738 and Olaparib
combination in biliary tract cancer patients who have failed to 1st-line chemotherapy.